Inhibition of Urinary Beta-Glucuronidase in Bladder Cancer Patients
Author Information
Author(s): E. Boyland, D. M. Wallace, D. C. Williams
Primary Institution: Chester Beatty Research Institute, Institute of Cancer Research: Royal Cancer Hospital, London
Hypothesis
If the urinary beta-glucuronidase activity in patients, in which new tumours would be expected to develop, could be inhibited, then these tumours should be prevented.
Conclusion
Oral administration of 1 g. saccharo-1:4-lactone every 6 hours decreases the enzyme activity in the urine by 90 percent.
Supporting Evidence
- Urinary beta-glucuronidase activity is almost always increased in the urine of patients with cancer of the bladder.
- Treatment with saccharo-1:4-lactone reduced the urinary beta-glucuronidase activity by 90 percent.
- Patients treated with sodium ammonium saccharate showed a 31 percent reduction in enzyme activity.
Takeaway
This study found that a special sugar compound can help lower harmful substances in the urine of bladder cancer patients, which might help prevent new tumors.
Methodology
Patients were treated with various inhibitors to decrease urinary beta-glucuronidase activity, and urine samples were collected to measure enzyme levels.
Limitations
The treatment has not been used long enough to draw definitive conclusions about clinical benefits.
Participant Demographics
Patients suffering from bladder cancer with a history of more than 2 years.
Want to read the original?
Access the complete publication on the publisher's website